Results 51 to 60 of about 26,327 (353)

The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study [PDF]

, 2017
Aims: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-
Aichner, Solveig, Albrecht, Diego, Bremerich, Jens, Delles, Christian, Freyhardt, Patrick, Heye, Tobias, Hrabak-Paar, Maja, Janka, Rolf, Keicher, Christian, Khder, Yasser, Langenickel, Thomas, Mayr, Michael, Ott, Christian, Schmieder, Roland E., Wagner, Frank, Yates, Denise   +15 more
core   +1 more source

What can we learn from SOCRATES: more questions than answers? [PDF]

, 2017
This editorial refers to ‘Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) Study’, by B ...
Cleland, John G.F., Mueller, Christian
core   +1 more source

Imbalance in Renal Vasoactive Enzymes Induced by Mild Hypoxia: Angiotensin-Converting Enzyme Increases While Neutral Endopeptidase Decreases

Frontiers in Physiology, 2018
Chronic hypoxia has been postulated as one of the mechanisms involved in salt-sensitive hypertension and chronic kidney disease (CKD). Kidneys have a critical role in the regulation of arterial blood pressure through vasoactive systems, such as the renin-
Carlos P. Vio, Carlos P. Vio, Daniela Salas, Carlos Cespedes, Jessica Diaz-Elizondo, Natalia Mendez, Natalia Mendez, Julio Alcayaga, Rodrigo Iturriaga   +8 more
doaj   +1 more source

IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline [PDF]

, 2016
Alzheimer’s disease (AD) is a devastating condition with no known effective treatment. AD is characterized by memory loss as well as impaired locomotor ability, reasoning, and judgment.
Chan, Ivy C. W., Cheung, Tom H., Fu, Amy K. Y., Fu, Wing-Yu, Hung, Kwok-Wang, Ip, Nancy Y., Liew, Foo Y., Mak, Deejay S. Y., Yuen, Michael Y. F., Zhang, Baorong, Zhou, Xiaopu   +10 more
core   +1 more source

Molecular Implications of natriuretic peptides in the protection from hypertension and target organ damage development [PDF]

, 2019
The pathogenesis of hypertension, as a multifactorial trait, is complex. High blood pressure levels, in turn, concur with the development of cardiovascular damage.
Forte, Maurizio, Marchitti, Simona, Rubattu, Speranza, Volpe, Massimo   +3 more
core   +1 more source

The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation

Рациональная фармакотерапия в кардиологии, 2023
Aim. To compare the change in quality of life indicators and the main clinical and instrumental parameters in patients with chronic heart failure (CHF) and functional mitral regurgitation (FMR) under the influence of sacubitril/valsartan compared with ...
A. S. Ryazanov, E. V. Shikh, O. V. Kechina, M. V. Makarovskaya, A. A. Kudryavtsev   +4 more
doaj   +1 more source

Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]

, 2017
Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T., Desai, Akshay S., Dickstein, Kenneth, Jhund, Pardeep S., Køber, Lars, McMurray, John J.V., Mogensen, Ulrik M., Packer, Milton, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +3 more sources

Potential Expanded Indications for Neprilysin Inhibitors [PDF]

Current Heart Failure Reports, 2017
The goal of this article is to review potential expanded indications for neprilysin inhibitors. This article reviews the rationale and design for ongoing and future trials of sacubitril/valsartan in cardiovascular and non-cardiovascular disease.Randomized trial data are lacking for use of sacubitril/valsartan in acute heart failure and advanced heart ...
Elizabeth Riddell, Justin M. Vader
openaire   +3 more sources

Elabela Protects Spontaneously Hypertensive Rats From Hypertension and Cardiorenal Dysfunctions Exacerbated by Dietary High-Salt Intake

Frontiers in Pharmacology, 2021
Objectives: Arterial hypertension, when exacerbated by excessive dietary salt intake, worsens the morbidity and mortality rates associated with cardiovascular and renal diseases.
Xavier Sainsily, Xavier Sainsily, Xavier Sainsily, David Coquerel, David Coquerel, Hugo Giguère, Hugo Giguère, Lauralyne Dumont, Lauralyne Dumont, Kien Tran, Kien Tran, Christophe Noll, Andrei L. Ionescu, Andrei L. Ionescu, Jérôme Côté, Jérôme Côté, Jean-Michel Longpré, Jean-Michel Longpré, André Carpentier, Éric Marsault, Éric Marsault, Olivier Lesur, Olivier Lesur, Philippe Sarret, Philippe Sarret, Mannix Auger-Messier, Mannix Auger-Messier   +26 more
doaj   +1 more source

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF [PDF]

, 2017
Aims: Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders.
Chen, Chen-Huan, Desai, Akshay S., Dukát, Andrej, Jhund, Pardeep S., Kristensen, Søren L., Køber, Lars, Lefkowitz, Martin P., McMurray, John J.V., Mogensen, Ulrik M., Packer, Milton, Prescott, Margaret F., Ramires, Felix, Rouleau, Jean L., Senni, Michele, Shi, Victor C., Solomon, Scott D., Swedberg, Karl   +16 more
core   +3 more sources